Abstract: Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

Abstract: A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: The present invention is a novel oral formulation for the administration of either celecoxib or allopurinol which provides a useful shelf life and is easy to re-suspend.

Abstract: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

Abstract: The disclosure relates to, among other things, pharmaceutical compositions, such as solid oral dosage forms, comprising itraconazole, methods of making the compositions, and methods of using the same for treating disorders including, but not limited to, fungal infections.

Abstract: The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

Abstract: A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, including at least: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.

Abstract: The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. The conjugates as well as the polymeric reagents used to form the conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided.

Abstract: This disclosure is directed to antibody-drug conjugates. More specifically, this disclosure is directed to compositions comprising (i) antibody-drug conjugates comprising benzodiazepines, and (ii) a small hydrophobic molecule, methods of treatment using the compositions, and methods of formulating the compositions. Furthermore, this disclosure is directed to methods of reducing reversible self-association in antibodies and in antibody-drug conjugates.

Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.

Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Abstract: The present invention relates to an enzymatic stimuli-responsive amphiphilic hybrid delivery system in micellar form, based on a hydrophilic polyethylene glycol (PEG) polymer conjugated to a hydrophobic dendron. The delivery system disassembles upon enzymatic stimuli/cleavage. The present invention further provides methods of use of the hybrid delivery system and to a kit comprising the same.

Abstract: Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as oxaliplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, colorectal cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.

Abstract: A polymeric material comprising a polyethylenimine-based material including the following moiety: attached thereto, wherein R1 is a group including at least one carbon atom and n is from 2 to 4 is disclosed. A method for preparing a polyethylenimine-based material is disclosed. A gene therapy method using a polymeric material including polyethylenimine-based material is also disclosed.

Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells (i.e., human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides.

Abstract: The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.

Abstract: The invention relates to nucleic acid constructs and gene therapy vectors that comprise an ATP7B variant for use in the treatment of conditions associated with a deficiency or dysfunction of Copper-transporting ATPase 2, and particularly of Wilson's disease. An AAV vector devised according to the invention significantly reduced urine Cu excretion, and liver Cu content in Wilson's disease mice treated with the vector, while ceruloplasmin activity was significantly restored. On the other hand, the administration of the vector resulted in the normalization of serum transaminases' levels and of liver histology, together with a marked reduction of the inflammatory infiltrate.

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

Abstract: Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing can be therapeutic. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration.

Abstract: A peptide for targeting MRP-14 has an amino acid sequence at least 80% identical to amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9, and SEQ ID NO: 10.

Abstract: Xenon based biosensors have the potential to detect and localize biomarkers associated with a wide variety of diseases. The development and nuclear magnetic resonance (NMR) characterization of cage molecules which encapsulate hyperpolarized xenon is imperative for the development of these xenon biosensors. We acquired 129Xe NMR spectra, and magnetic resonance images and a HyperCEST saturation map of cucurbit[6]uril (CB6) in whole bovine blood. We observed a mean HyperCEST depletion of 84% (n=5) at a concentration of 5 mM and 74% at 2.5 mM. Additionally, we collected these data using a pulsed HyperCEST saturation pre-pulse train with a SAR of 0.025 W/kg which will minimize any potential RF heating in animal or human tissue.

Abstract: The present invention provides novel liposomes comprising Gd.DOTA.DSA (gadolinium (III) 2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N?-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid), characterised in that said liposome further comprises a neutral, fully saturated phospholipid component (e.g. DSPC (1,2-distearoyl-sn-glycero-3-phospocholine]), which are of particular use in the preparation of magnetic resonance contrast agents for enhancing a magnetic resonance image of tumours in a mammal.

Abstract: The present invention provides a method for the treatment of malignant neoplasias comprising the step of administering an L-phenylalanine conjugated to a beta- or alpha-emitting isotope to a subject in the need thereof. Moreover, the invention provides a method for the monitoring of the progress of such treatment of malignant neoplasias.

Abstract: Among the various aspects of the present disclosure is the provision of compositions of imaging agents and methods for use in detecting, monitoring, and evaluating CCR2 associated diseases, disorders, and conditions.

Abstract: The invention relates to a cleaning system for a set of instruments associated or in contact with an image plate readout device, as well as to a readout device comprising the cleaning system. The cleaning system comprises a disinfecting element, which emits electromagnetic radiation and/or ultrasonic radiation capable of destroying disease carriers, and which is adapted to emit said radiation towards an image plate conveyor mechanism encompassed by the image plate readout device.

Abstract: The present invention provides a sterilizer for a portable electronic device, comprising: a main body unit; a charge pin terminal unit coupled to one side surface of the main body unit and inserted into a charge slot of the portable electronic device; a cable coupling slot provided at the other side surface of the main body unit such that a charge terminal of a charge cable is inserted into the cable coupling slot; and a sterilizing LED module provided at one side surface of the main body unit, wherein LED rays emitted from the sterilizing LED module include visible rays, which are harmless to the human body.

Abstract: A germicidal device is disclosed. The germicidal device may include a flexible panel that can be rolled up and/or folded. A plurality of LEDs embedded in the panel and a plurality of lenses are embedded in the panel. The panel includes an input connector coupled to the panel that receives input at a first voltage from a power source. The LEDs are coupled to the input connector and provided a second voltage that is suitable for operating the LEDs. The panel also includes one or more output connectors on the panel. The output connectors provide the first voltage as an output voltage from the panel. The panel may be coupled to additional panels with the additional panels receiving the first (output) voltage from the first panel as input voltage to the additional panels.

Abstract: The present invention is an apparatus that is contained inside the confined space of a Point of Sale Cash Register, Cash Drawer and is designed specifically to sterilize currency and or additional items placed inside the drawer, automatically. The invention includes UVC lighting source(s), either CCFL tube (spanning the length of the enclosure, and located centrally above the denomination separation slots, or by high powered LED-UVC with printed circuit board and located directly above the tray/till slots). The upper, interior surface of the enclosure is lined with highly reflective material. Each slot in the cash tray/till is also lined with highly reflective material. The system is controlled electronically, via an external power supply, that is connected to a dedicated circuit board, which is located in the rear of the enclosure, and is activated by a photo sensor each time the drawer is opened. A programmable timer initializes at the moment the drawer is fully closed.

Abstract: A plasma liquid generating device includes a tube, a plasma generating module, a flow limiting unit, and a position limiting member. The tube has at least an air inlet and a flow channel outlet. The plasma generating module is disposed adjacent to the air inlet and configured to generate plasma. The flow limiting unit is detachably disposed in the tube, and a distance between the flow limiting unit and the flow channel outlet is greater than a distance between the air inlet and the flow channel outlet. The position limiting member is detachably disposed at the flow channel outlet to limit the position of the flow limiting unit.

Abstract: A water treatment dispensing apparatus has a container for holding water from a water supply and a water disinfectant cartridge located within the container. A housing attached to the container and connected to the cartridge directs water from the cartridge to a remote location, such as a dental instrument. An air pressure device supplies water under pressure to the container to force water to flow through the cartridge and to the remote location.

Abstract: A method of disinfecting a fluid circuit of a thermal control for delivering temperature controlled fluid to at least one patient therapy device comprises the steps of providing an aqueous mixture comprising a disinfectant and circulating the aqueous mixture in the thermal control unit to disinfect the fluid circuit. The disinfectant comprises free-chlorine, a phenol, hydrogen peroxide (H2O2), or combinations thereof. If the disinfectant comprises free-chlorine, the free-chlorine is provided by a chlorinated isocyanurate (e.g. sodium dichloroisocyanurate; NaDCC). In addition, the free-chlorine is present in the aqueous mixture in an amount of at least about 100 parts per million (ppm). If the disinfectant comprises the phenol, the phenol is natural (e.g. thymol). In addition, the phenol is present in the aqueous mixture in an amount of at least about 10,000 ppm. If utilized, H2O2 is present in the aqueous mixture in an amount of at least about 5,000 ppm.

Abstract: The method for producing dinitrogen tetraoxide comprising the steps of operating a decompressor (3) to reduce a pressure within the space area (2) maintained in the hermetically sealed condition to the decompressed or vacuum condition below the saturated vapor pressure curve of dinitrogen tetraoxide, supplying the dinitrogen tetraoxide liquid as a sterilant feedstock from a vessel (4) to a spray device (25) while preventing gasification of the dinitrogen tetraoxide liquid on the way between the vessel (4) and spray device (25), and spraying the dinitrogen tetraoxide liquid through the spray device (25) into the space area (2) under the decompressed or vacuum condition to, at the time of the spraying, gasify at least some of the dinitrogen tetraoxide liquid within the space area (2) decompressed below the saturated vapor pressure curve.

Abstract: A packaging device including a receiving compartment for medical products to be sterilized or having been sterilized, the receiving compartment being sealable in a sterile manner; a carrier for hanging and/or guiding and/or handling the packaging device, wherein the carrier extends into the interior of the receiving compartment and includes at least one accurately fitting mount for a section of a medical product to be sterilized or having been sterilized. Also, secondary packaging for accommodating a plurality of such packaging devices.

Abstract: In the present invention, a device, system and associated method is provided, as a compact, automated and self-contained data logger with capability of withstanding conditions used in sterilizing reusable medical device equipment/components. The device includes one or more sensors to automatically sense and store information on the parameters of various autoclave cycle(s) for the component associated with the tracking device and their respective timestamps of each autoclave cycle(s). This information is stored in a data record on the tracking device for the individual component. The data record can be used as evidence of valid sterilization cycles for the component and can also provide information for the host system and/or the user of the status for the component, including the last time the component was sterilized, the time between sterilization cycles, the time for replacement of the component, and too warn if the device was returned to service without proper sterilization.

Abstract: An odor mitigating caddy includes first and second frame members each having opposed front and rear edges, respective rear edges being pivotally coupled together with a living hinge such that the frame members are selectively movable between a closed configuration at which the front edges, respectively, are generally adjacent one another and an open configuration at which the front edges, respectively, are separated from one another. The first and second frame members are defined by peripheral edges and include first and second grate members extending between respective peripheral edges, respectively. A porous odor mitigating sheet is held between the frame and grate members. First and second frame members include aligned first and second hook members so that the caddy is selectively suspended from a closet rod or the like.

Abstract: The invention provides an air purifier (1) comprising a catalytic converter (100), the catalytic converter (100) comprising (i) a catalytically active material (120) and (ii) a heatable material (130) in thermal contact with said catalytically active material (120), wherein the heatable material (130) is heatable by one or more of an alternating electrical field and an alternating magnetic field, the air purifier (1) further comprising a field generator (140), configured free from electrical contact with the heatable material (130) and configured to heat during operation of the air purifier (1) the heatable material (130) by one or more of the alternating electrical field and the alternating magnetic field.

Abstract: The present invention relates to an air cleaner and, more particularly, to an air cleaner provided with a housing divided into an outer housing and an inner housing, wherein the outer housing and the inner housing are separated from one another, a photocatalytic filter and a collection filter are installed in the inner housing, and air flows even through the space between the inner housing and the outer housing.

Abstract: A storage apparatus according to an embodiment may include a body having a storage space of storage products and an air purifying module coupled to the body. The air purifying module may include a light emitting diode part disposed along a passage of air to provide ultraviolet light, and a filter part disposed adjacent to the light emitting diode part.

Abstract: A pasty two-component polymethacrylate bone cement comprising a pasty component A, containing AI at least one distillable methacrylate monomer for radical polymerisation; AII at least one polymer soluble in AI; AIII at least one particulate polymer with a particle size of no more than 500 ?m that is not soluble in AI; AIV at least one radical stabiliser; and AV at least one aromatic amine accelerator; and a pasty component B, containing BI dibenzoyl peroxide; BII at least one substance that is not subject to radical polymerisation and is liquid at room temperature, whereby the solubility of dibenzoyl peroxide in this substance at room temperature is less than 5.0% by weight and, whereby the weight fraction of liquid substance BII in the self-curing cement dough is less than 2.0% by weight. Also disclosed is a method for producing a self-curing bone cement dough using the pasty two-component polymethacrylate bone cement.

Abstract: The present invention relates to a method of providing a graft scaffold for cartilage repair, particularly in a human patient. The method of the invention comprising the steps of providing particles and/or fibres; providing an aqueous solution of a gelling polysaccharide; providing mammalian cells; mixing said particles and/or fibres, said aqueous solution of a gelling polysaccharide and said mammalian cells to obtain a printing mix; and depositing said printing mix in a three-dimensional form. The invention further relates to graft scaffolds and grafts obtained by the method of the invention.

Abstract: Disclosed are compositions, methods and processes for fabricating and using a device or other implement including a surface or surfaces having a nanoscale or microscale layer or coating of Si—O—N—P. These coatings and/or layers may be continuous, on the surface or discontinuous (e.g., patterned, grooved), and may be provided on silica surfaces, metal (e.g., titanium), ceramic, and combination/hybrid materials. Methods of producing an implantable device, such as a load-bearing or non-load-bearing device, such as a bone or other structural implant device (load-bearing), are also presented. Craniofacial, osteogenic and disordered bone regeneration (osteoporosis) uses and applications of devices that include at least one surface that is treated to include a nanoscale or microscale layer or coating of Si—O—N—P are also provided. Methods of using the treated and/or coated devices to enhance enhanced vascularization and healing at a treated surface of a device in vivo, is also presented.

Abstract: Methods for treating tissue matrices and tissue matrices produced according to the methods are provided.

Abstract: Method of the osteoreparative processes' correction and/or bone defect restoration by means of human cell-based products (cell and/or tissue transplants) and the method of its manufacturing. The invention a creates and establishes conditions for osteoreparative processes restoration in destroyed bone tissue by osteoreparation cell sources restoration as the result of use cell technologies and bone tissue engineering methods, e.g. scaffold-guided regeneration, particularly by means of cell transplantation by injection and/or transplantation of original three-dimensional osteoreparative prevascularized graft (3D-OPG). Manufacturing of medical products and preparations of the product based on human cells (cell and/or tissue transplants) is dedicated for impaired osteoreparative processes correction and/or bone defect restoration.

Abstract: The invention relates to an implant material for filling bone defects, for bone regeneration, and for bone tissue engineering, to an implant comprising said material, and to methods for manufacturing such an implant. The hybrid implant material according to the invention comprises: a biodegradable polymer P soluble in at least one solvent S1 and insoluble in at least one solvent S, different from the solvent S1; and a bioactive glass made of SiO2 and CaO and optionally containing P2O5 and/or optionally doped with strontium, characterized in that said implant includes a layering of a porous part having more than 90% by number of pores whose largest dimension is greater than or equal to 100 ?m, and a dense part (2, 20, 200, 2000, 20000) having more than 80% by number of pores whose largest dimension is less than 50 ?m. The invention is useful in the field of bone regeneration, particularly in the field of bone tissue engineering.

Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.

Abstract: The invention relates to components for fusing vertebral bodies and to methods for the production and use thereof.

Abstract: A polymer film can be adjusted to movement or a fine uneven surface of a living body and has excellent ability to adhere to a biological tissue. The polymer film includes a block copolymer having a structure in which branched polyalkylene glycol and polyhydroxyalkanoic acid are bound to each other, wherein the polymer film has a film thickness of 10 to 1000 nm. The branched polyalkylene glycol has at least three terminal hydroxyl groups per molecule, the mass percentage of the branched polyalkylene glycol relative to the total mass of the block copolymer is 1% to 30%, and a value obtained by dividing the average molecular weight of polyhydroxyalkanoic acid in the block copolymer by X that is the number of terminal hydroxyl groups present per a single molecule of the branched polyalkylene glycol is 10000 to 30000.

Abstract: A process for coating parylene onto a metal surface, such as a medical device, that has been textured by a series of laser pulses. The laser pulses can be overlapping or rastered. The textured portion of the metal surface and parylene coating can form a strong mechanical interlock. The bond created by using the laser texturing process can result in a cohesive failure of the parylene and not an adhesive failure of the bonding.